1. Researchers call out Gilead over diversity of remdesivir trials — Bristol-Myers commits $300M to combat racial disparities — Goldman predicts at least one coronavirus vaccine approval before the end of 2020 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Why the increase in stock this week?

Discussion in 'Savient' started by Anonymous, Jun 6, 2013 at 2:18 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Anyone have a legitimate reason why the stock has shot up this week?
     

  2. Anonymous

    Anonymous Guest

    Because there are a lot of idiots on Wall Street!
     
  3. Anonymous

    Anonymous Guest

    Or 'CRACK' management team of Lou,Smo and the other smucks spent $25 to buy 100,000 shares of Savient stock to boost the stock price!
     
  4. Anonymous

    Anonymous Guest

    Oh you yahoo losers are digging for any information you can possibly gather. Trust me,,,nothing has changed. We are on fumes and the end will be here in the near future. Lou is just as pathetic as always.
     
  5. Anonymous

    Anonymous Guest

    can you say "pump and dump"?
     
  6. Anonymous

    Anonymous Guest

    How about another round of layoffs?

    At least two more were let go, global supply and qwality (we can't spell qwality without U)......more to follow.......and then the silence of the grave
     
  7. Anonymous

    Anonymous Guest

    short sellers covering
     
  8. Anonymous

    Anonymous Guest

    Slashing research, SG&A, headcount and we are still underwater by $161,985,000 if you believe the Q1 2013 numbers. Sales were $4,400,000 ($4.4MM) for the quarter.

    It will only take 92 YEARS at this rate to become a break even company.
     
  9. Anonymous

    Anonymous Guest

    There will not be anyone left except LF and his crew, waiting to collect their golden parachutes
     
  10. Anonymous

    Anonymous Guest

    DOn't understand.....can't figure out why SVNT should still be in business. There is no justification for this company to remain an ongoing business entity. It simply does not cover its costs of existence.............its fundamental premise is largely wrong. The severe gout patients aren't in rheumatology offices........that's why they are sick. SVNT isn't structured to find them when they largely don't get to the good specialiss who would not let them get that sick in the first place. DUH!
     
  11. Anonymous

    Anonymous Guest

    What's the stock price now?!
     
  12. Anonymous

    Anonymous Guest

    Really? You can't figure out how to look up the current stock price? You are the perfect Savient investor.....clueless!! Currently at 63 cents, and not much different from before.
     
  13. Anonymous

    Anonymous Guest

    Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients

    "Four deaths occurred in the treatment group. Of the four deaths in the treatment groups, two were attributed to cardiac events and occurred in patients with four or more cardiovascular risk factors at baseline. Of the two non-cardiovascular related deaths, one was attributed to renal failure."

    This is the old news....has Krystexxa killed anyone lately?
     
  14. Anonymous

    Anonymous Guest

    The only thing Krystexxa has killed is my career and the company.
     
  15. Anonymous

    Anonymous Guest

    The stock is at 56 cents today. We have no hope of selling enough drug to cover expenses, layoffs continue in an effort to cut costs. At some point the current supply will expire and that will be the end if bankruptcy does not hit first. There is no money to make another batch and there is not enough interest is this product to warrant doing so. Pack up your bags, the three gay caballeros will be closing the doors soon. Finding another job in this market sucks....but I keep looking. Having this turd on my resume does not help.
     
  16. Anonymous

    Anonymous Guest

    Just wait for what happens tonight...
     
  17. Anonymous

    Anonymous Guest

    Will it be another price increase? Maybe another exciting abstract being presented at an obscure meeting or non-peer reviewed journal?
     
  18. Anonymous

    Anonymous Guest

    and it's just announced. Go see the company news on website.
     
  19. Anonymous

    Anonymous Guest